These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26780380)

  • 1. Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers.
    Ung KT; Chan HK
    Eur J Pharm Sci; 2016 Mar; 84():46-54. PubMed ID: 26780380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
    Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.
    Leung SS; Tang P; Zhou QT; Tong Z; Leung C; Decharaksa J; Yang R; Chan HK
    AAPS J; 2015 Nov; 17(6):1407-16. PubMed ID: 26201967
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
    [No Abstract]   [Full Text] [Related]  

  • 6. Design of spray dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung dose.
    Ung KT; Rao N; Weers JG; Huang D; Chan HK
    Int J Pharm; 2016 Sep; 511(2):1070-9. PubMed ID: 27480399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
    Kolanjiyil AV; Kleinstreuer C; Sadikot RT
    Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
    Delvadia RR; Longest PW; Hindle M; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro dry powder inhaler formulation performance considerations.
    Ziffels S; Bemelmans NL; Durham PG; Hickey AJ
    J Control Release; 2015 Feb; 199():45-52. PubMed ID: 25497311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of altitude on inhaler performance.
    Titosky JTF; Morin CMD; Suderman JD; Olfert JS; Finlay WH; Vehring R
    J Pharm Sci; 2014 Jul; 103(7):2116-2124. PubMed ID: 24890630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Powder aerosol delivery through nasal high-flow system: In vitro feasibility and influence of process conditions.
    Okuda T; Tang P; Yu J; Finlay WH; Chan HK
    Int J Pharm; 2017 Nov; 533(1):187-197. PubMed ID: 28830783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children.
    Farkas D; Hindle M; Bonasera S; Bass K; Longest W
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):83-98. PubMed ID: 31464559
    [No Abstract]   [Full Text] [Related]  

  • 16. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Dry Powder Inhaler Patient Interfaces for Improved Aerosol Delivery to Children.
    Bass K; Longest W
    AAPS PharmSciTech; 2020 May; 21(5):157. PubMed ID: 32451773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Pierce and inhale" design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs.
    Martinelli F; Balducci AG; Rossi A; Sonvico F; Colombo P; Buttini F
    Int J Pharm; 2015 Jun; 487(1-2):197-204. PubMed ID: 25843756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a novel dry powder inhaler.
    Zhang X; Ma Y; Zhang L; Zhu J; Jin F
    Int J Pharm; 2012 Jul; 431(1-2):45-52. PubMed ID: 22543053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.
    Clark AR; Weers JG; Dhand R
    J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):1-11. PubMed ID: 31613682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.